Table S1.
Results of sensitivity analyses using a 60-day and 120-day grace period in the Cohort 2
| 60-day grace period
| |||||||
|---|---|---|---|---|---|---|---|
| Outcome | ASA use | No. of persons | No. of endpoint | Sum of person-years | Incidence rate/1, 000 PYRs (95% CI) | Adjusted IRD (95% CI) | Adjusted IRR (95% CI) |
| Major bleeding | No | 367,326 | 5,370 | 1,093,950 | 4.91 (4.78, 5.04) | – | – |
| Major bleeding | Yes | 367,326 | 5,428 | 543,420 | 9.99 (9.72, 10.25) | 5.08 (4.78, 5.38) | 2.03 (1.96, 2.11) |
| Cerebral hemorrhage | No | 367,326 | 1,573 | 1,093,950 | 1.44 (1.37, 1.51) | – | – |
| Cerebral hemorrhage | Yes | 367,326 | 1,256 | 543,420 | 2.31 (2.18, 2.44) | 0.87 (0.73, 1.02) | 1.61 (1.49, 1.73) |
| Gastrointestinal bleeding | No | 367,326 | 3,797 | 1,093,950 | 3.47 (3.36, 3.58) | – | – |
| Gastrointestinal bleeding | Yes | 367,326 | 4,172 | 543,420 | 7.68 (7.44, 7.91) | 4.21 (3.95, 4.46) | 2.21 (2.12, 2.31) |
|
| |||||||
| 120-day grace period | |||||||
|
| |||||||
| Outcome | ASA use | No. of persons | No. of endpoint | Sum of person-years | Incidence rate/1,000 PYRs (95% CI) | Adjusted IRD (95% CI) | Adjusted IRR (95% CI) |
|
| |||||||
| Major bleeding | No | 367,326 | 5,370 | 1,093,950 | 4.91 (4.78, 5.04) | – | – |
| Major bleeding | Yes | 367,326 | 7,064 | 748,210 | 9.44 (9.22, 9.66) | 4.53 (4.28, 4.79) | 1.92 (1.86, 1.99) |
| Cerebral hemorrhage | No | 367,326 | 1,573 | 1,093,950 | 1.44 (1.37, 1.51) | – | – |
| Cerebral hemorrhage | Yes | 367,326 | 1,683 | 748,210 | 2.25 (2.14, 2.36) | 0.81 (0.68, 0.94) | 1.56 (1.46, 1.68) |
| Gastrointestinal bleeding | No | 367,326 | 3,797 | 1,093,950 | 3.47 (3.36, 3.58) | – | – |
| Gastrointestinal bleeding | Yes | 367,326 | 5,381 | 748,210 | 7.19 (7.00, 7.38) | 3.72 (3.50, 3.94) | 2.07 (1.99, 2.16) |
Abbreviations: ASA, acetylsalicylic acid; PYRs, person-years; IRD, incidence rate difference; IRR, incidence rate ratio; 95% CI, 95% confidence interval.